http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008546754-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 |
| filingDate | 2006-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2008-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2008546754-A |
| titleOfInvention | Pharmaceutical combinations containing pyrazole derivatives as protein kinase modulators |
| abstract | The present invention provides a combination comprising an auxiliary compound (eg, one, two or more auxiliary compounds) and a compound of formula (I) having protein kinase B inhibitory activity: [Chemical 1] Wherein A is a saturated hydrocarbon linker group containing 1 to 7 carbon atoms, the linker group having a chain length of up to 5 atoms extending between R 1 and NR 2 R 3. And has a chain length of up to 4 atoms extending between E and NR 2 R 3 ; provided that one of the carbon atoms of the linker group may be optionally substituted with an oxygen or nitrogen atom; , The carbon atom of linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy; provided that the hydroxy group, if present, relates to NR 2 R 3 Not located at the α carbon atom and the oxo group, if present, is located at the α carbon atom with respect to NR 2 R 3 ; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R 1 Is aryl or heteroary Is a group; R 2, R 3, R 4 and R 5 are as defined in the claims. Further provided are patient packages, pharmaceutical kits and packages and compositions containing the combination, methods of making the combination and their use in combination therapy as anticancer agents. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016527227-A |
| priorityDate | 2005-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2992.